Galderma Group Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Flemming Ornskov

Chief executive officer

US$22.0m

Total compensation

CEO salary percentage	10.95%
CEO tenure	4.7yrs
CEO ownership	n/a
Management average tenure	2.6yrs
Board average tenure	4.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Flemming Ornskov's remuneration changed compared to Galderma Group's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2026	n/a	n/a	US$863m
Mar 31 2026	n/a	n/a	US$738m
Dec 31 2025	US$22m	US$2m	US$613m
Sep 30 2025	n/a	n/a	US$496m
Jun 30 2025	n/a	n/a	US$378m
Mar 31 2025	n/a	n/a	US$305m
Dec 31 2024	US$21m	US$2m	US$231m

Compensation vs Market: Flemming's total compensation ($USD22.05M) is above average for companies of similar size in the US market ($USD14.74M).

Compensation vs Earnings: Flemming's compensation has been consistent with company performance over the past year.

CEO

Flemming Ornskov (68 yo)

4.7yrs

Tenure

US$22,045,495

Compensation

Dr. Flemming Ornskov, M.D., MBA, MPH, serves as Chief Executive Officer at Galderma S.A. He is a Director and Chief Executive Officer of Galderma Group AG since 2022. He served as Member of the Supervisory...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Flemming Ornskov	CEO & Director	4.7yrs	US$22.05m	no data
Luigi Felice Corte	Chief Financial Officer	less than a year	no data	no data
Adrian Murphy	Head of Global Operations	4.3yrs	no data	no data
Emil Ivanov	Head of Strategy	no data	no data	no data
Nakisa Serry	General Counsel	less than a year	no data	no data
Christian Marcoux	Chief Communications Officer	no data	no data	no data
Desislava Lazarova	Global Head of Customer Education & Training	no data	no data	no data

2.6yrs

Average Tenure

57yo

Average Age

Experienced Management: GDER.F's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Flemming Ornskov	CEO & Director	4.7yrs	US$22.05m	no data
Thomas Ebeling	Independent Chairman	4.7yrs	US$1.21m	no data
L. Browne	Independent Director	4.7yrs	US$359.77k	no data
Marcus Brennecke	Director	2.7yrs	no data	no data
Sherilyn S. McCoy	Independent Vice Chairman	4.7yrs	US$410.26k	no data
Maria Hilado	Independent Director	4.7yrs	US$403.95k	no data
Harry Kirsch	Independent Director	less than a year	no data	no data
Karen Ling	Independent Director	4.7yrs	US$378.70k	no data
Roberto de Oliveira Marques	Independent Director	1.4yrs	US$238.58k	no data
Delphine Viguier-Hovasse	Representative Director	less than a year	no data	no data
Samuel Du Retail	Representative Director	less than a year	no data	no data

4.7yrs

Average Tenure

64yo

Average Age

Experienced Board: GDER.F's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/09 07:54
End of Day Share Price	2026/09/09 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Galderma Group AG is covered by 29 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yihan Li	Barclays
James Gordon	Barclays
Fulvio Cazzol	Berenberg

Galderma Group Management

Management criteria checks 3/4

Key information

Recent management updates

Galderma Group AG Approves Board Appointments

Galderma Group AG, Annual General Meeting, Apr 22, 2026

Galderma Group AG Announces the Appointment of Luigi La Corte as Chief Financial Officer, Effective May 1, 2026

Galderma Group AG Announces Departure of Thomas Dittrich as Chief Financial Officer

Galderma Group AG, Annual General Meeting, Apr 23, 2025

Recent updates

Galderma Receives European Union Approval for Restylane Shaype Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

Galderma Provides Progress Updates Regarding Regulatory Review of its Pending Biologics License Application for RelabotulinumtoxinA with U.S. Food and Drug Administration

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States

Galderma Group AG Approves Payment of Dividend, Payable on April 28, 2026

Galderma Group AG Approves Board Appointments

Galderma Group AG Launches Alastin Regenerating Skin Nectar with Trihex+

Galderma Reports Interim Data from Investigator-Initiated Trials on Sculptra and Restylane for Aesthetic Changes in Weight Loss and Menopause

Galderma Launches ALASTIN Signature Practices

Galderma Announces Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 with Moderate-To-Severe Atopic Dermatitis

Galderma Receives U.S. FDA Approval for Restylane Contour for the Correction of Temple Hollowing

Galderma Group AG, Annual General Meeting, Apr 22, 2026

Galderma Group AG Provides Earnings Guidance for the Full-Year of 2026

Galderma's Nemluvio (Nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis Up to Three Years

Galderma Announces Triple Approval of New Restylane Syringe in the EU, the U.S., and Canada

Galderma Group AG Announces the Appointment of Luigi La Corte as Chief Financial Officer, Effective May 1, 2026

Galderma Expands Restylane Portfolio in Japan with Launch of OBT Hyaluronic Acid Injectables Restylane Defyne™? and Refyne

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission

Galderma Group AG to Report Fiscal Year 2025 Results on Mar 05, 2026

Galderma to Present Data on its Innovative and Industry-Leading Neuromodulator Portfolio

Galderma Releases New Clinical Data Confirms Nemluvio®? (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis

Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults with Chronic Pruritus Of unknown Origin

Galderma Group AG to Report First Half, 2026 Results on Jul 23, 2026

Galderma Presents New Data from Its Injectable Aesthetics Portfolio and Pipeline

Galderma Receives U.S. FDA Approval for Restylane Lyft for the Enhancement of the Chin Profile

Galderma Group AG Revises Earnings Guidance for the Full Year 2025

Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education

Galderma Launches Transformative Skincare Segment with Cetaphil's New Skin Activator Hydrating & Firming Line

Galderma's Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin

Galderma Announces Updates from Its Portfolio At the 34Th European Academy of Dermatology and Venereology Congress

Galderma Introduces Cetaphil Nourishing Oil to Foam Cleanser

Galderma Group Ag Raises Earning Guidance for 2025

Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction with Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss

Galderma Group AG Announces Departure of Thomas Dittrich as Chief Financial Officer

Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients with Systemic Sclerosis and Chronic Pruritus of unknown Origin

Galderma Announces Data from New Interim Analysis of Study Investigating the Long-Term Safety and Efficacy of Nemluvio in Moderate-To-Severe Prurigo Nodularis

Galderma’S Nemluvio® (Nemolizumab) Receives National Institute for Health and Care Excellence (Nice) Recommendation for Moderate-To-Severe Atopic Dermatitis in England and Wales

Galderma Announces Two-Year Data from A New Interim Analysis of A Long-Term Extension Study Investigating the Safety and Efficacy of Nemluvio in Moderate-To-Severe Atopic Dermatitis

Galderma Launches Sculptra in China

Galderma Group AG, Annual General Meeting, Apr 23, 2025

Galderma Group AG announces Annual dividend, payable on April 29, 2025

Galderma Pushes the Innovation Frontier with Updates from Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community

Galderma Group AG Proposes Dividend Distribution , Payable on April 29, 2025

Galderma Group AG to Report Fiscal Year 2024 Final Results on Mar 21, 2025

Galderma Group AG Announces Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

Galderma's Nemluvio®? (Nemolizumab) Approves in the European Union for Moderate-To-Severe Atopic Dermatitis and Prurigo Nodularis

Galderma Announces New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-Lasting Aesthetic Improvement with Relabotulinumtoxina (Relfydess)

Galderma to Present Latest Updates from Its Innovative Aesthetics Portfolio At the International Master Course on Aging Science World Congress 2025

Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as A Result of Medication-Driven Weight Loss

Galderma Receives U.S. FDA Approval for Nemluvio for Patients with Moderate-to-Severe Atopic Dermatitis

CHMP Recommends Approval of Galderma's Nemolizumab for Moderate-To-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

Galderma Group AG to Report Fiscal Year 2024 Results on Mar 06, 2025

Galderma Group AG to Report First Half, 2025 Results on Jul 24, 2025

Galderma Group AG Revises Earnings Guidance for the Year 2024

Galderma Owners Reportedly Aim to Sell USD 1.2 Billion Stake

Galderma Receives U.S. FDA Approval for Nemluvio (nemolizumab) for Adult Patients Living With Prurigo Nodularis

Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe

Galderma Group AG Updates Earnings Guidance for the Year 2024

Galderma Introduces High Potency Cetaphil Serums Designed for Sensitive Skin

Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities At Its Center of Excellence